Positive Clinical Data: Recent posts on X have been buzzing with news about Lucid Diagnostics after the company released data from an 18-month real-world study involving nearly 12,000 patients. The study highlighted a 95% success rate for its EsoGuard procedures, with most completed in under two minutes and no serious adverse events reported. This has sparked considerable interest among investors tracking the stock.
Analyst Upgrades: Adding to the momentum, discussions on X also noted a recent upgrade from a major analyst firm, raising the price target for LUCD to $8.25 with a buy rating. Many users are pointing to growing test volumes as a potential driver, though some caution about near-term revenue challenges due to deferred collections. The mix of optimism and caution keeps the conversation dynamic.
Note: This discussion summary was generated from an AI condensation of post data.
Lucid Diagnostics Insider Trading Activity
Lucid Diagnostics insiders have traded $LUCD stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LUCD stock by insiders over the last 6 months:
- DENNIS MATHEIS purchased 100,000 shares for an estimated $101,840
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Lucid Diagnostics Revenue
Lucid Diagnostics had revenues of $1.2M in Q3 2025. This is an increase of 3.33% from the same period in the prior year.
You can track LUCD financials on Quiver Quantitative's LUCD stock page.
Lucid Diagnostics Hedge Fund Activity
We have seen 54 institutional investors add shares of Lucid Diagnostics stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TWO SEAS CAPITAL LP added 3,000,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,030,000
- AWM INVESTMENT COMPANY, INC. added 2,990,500 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,020,405
- GHISALLO CAPITAL MANAGEMENT LLC added 2,960,066 shares (+inf%) to their portfolio in Q3 2025, for an estimated $2,989,666
- ABERDEEN GROUP PLC added 2,500,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $2,525,000
- MASTERS CAPITAL MANAGEMENT LLC added 1,272,000 shares (+46.6%) to their portfolio in Q3 2025, for an estimated $1,284,720
- PERKINS CAPITAL MANAGEMENT INC added 1,127,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,138,270
- ALYESKA INVESTMENT GROUP, L.P. added 644,839 shares (+87.3%) to their portfolio in Q3 2025, for an estimated $651,287
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Lucid Diagnostics Analyst Ratings
Wall Street analysts have issued reports on $LUCD in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Ascendiant Capital issued a "Buy" rating on 12/10/2025
- Needham issued a "Buy" rating on 11/13/2025
- BTIG issued a "Buy" rating on 09/10/2025
To track analyst ratings and price targets for Lucid Diagnostics, check out Quiver Quantitative's $LUCD forecast page.
Lucid Diagnostics Price Targets
Multiple analysts have issued price targets for $LUCD recently. We have seen 3 analysts offer price targets for $LUCD in the last 6 months, with a median target of $3.0.
Here are some recent targets:
- Edward Woo from Ascendiant Capital set a target price of $8.25 on 12/10/2025
- Mike Matson from Needham set a target price of $3.0 on 11/13/2025
- Mark Massaro from BTIG set a target price of $2.5 on 09/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
